Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
Candel Therapeutics, Inc. (CADL)
Company Research
Source: GlobeNewswire
NEEDHAM, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced three presentations at the 16th Annual International Oncolytic Virotherapy Conference (IOVC), taking place October 27-30, 2024, in Rotterdam, the Netherlands. The presentations will showcase Candel’s advancements in innovative viral immunotherapies, including new data from the ongoing phase 1b clinical trial of CAN-3110 in recurrent high-grade glioma (rHGG), a presentation on a new multimodal immunotherapy candidate from the enLIGHTEN™ Discovery Platform, and a Company overview, focused on Candel’s broad clinical and preclinical pipeline. In detail: E. Antonio Chiocca, MD, PhD, Professor of Neurosurgery at Harvard Medical School, and recently appointed Executive Director of the Center for Tumors of the Nervous System (
Show less
Read more
Impact Snapshot
Event Time:
CADL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CADL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CADL alerts
High impacting Candel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CADL
News
- Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Diakonos Oncology Appoints Laura Aguilar, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Candel Therapeutics reports Q3 results [Seeking Alpha]Seeking Alpha
- Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswire
CADL
Analyst Actions
- 11/18/24 - HC Wainwright
CADL
Sec Filings
- 11/21/24 - Form 4
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- CADL's page on the SEC website